A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 06 Jan 2023 This study protocol amended as time frame for primary endpoint (Objective Response Rate) changed to 2 years from 4 months.
- 15 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.